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Background
MYH-Associated Polyposis (MAP) is an autosomal
recessive condition caused by bi-allelic mutations in
MYH. Individuals with MAP tend to develop numerous
polyps in their colon and rectum and have an increased
risk of developing colorectal cancer. Recommendations
for MAP treatment vary in the literature ranging from
frequent surveillance colonoscopy to prophylactic sur-
gery depending on polyp burden. The aim of this study
w a st or e p o r tt h em a n a g e m e n ta n do u t c o m eo fas i n g l e
institution series of patients with MAP.
Methods
Patients with biallelic mutations in MYH were accrued
over 23 years from a query of a comprehensive polypo-
sis database using Cologene© software. Demographics,
family history, upper and lower endoscopy frequency,
polyp burden, and cancer data, and treatment were
recorded.
Results
Thirty-four patients from 26 families with MAP were
included. There were 24 cancers in 14 patients. Four of
the patients had multiple cancers (14 total), each with a
rectal cancer plus a more proximal cancer. 3 patients
had more than 2 colorectal cancers. Of the 24 colorectal
cancers, 10 (42%) were right sided and 14 (58%) were
left sided. Most cancers (90%) were stage I or II and
10% were stage III as shown in Table 1.
All patients also had colorectal adenomas. Median
polyp number is 20 (range 1-115) for patients with soli-
tary cancer and for multiple cancers median was 100
(range 50-120) (Table 2).
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Table 1 Demographic Details
Synchronous
(N=4)
Solitary (N=10) No Cancer
(N=20)
Gender M – 50%
F – 50%
M – 60%
F – 40%
M – 90%
F – 10%
Age Mean 40.8 Mean 51 Mean 54
Family
History
3/4 yes 4/10 yes (one
unknown)
6/20 yes
Table 2 Cancer Details
Synchronous (N=4) Solitary (N=10) No Cancer (N=20)
Number of polyps Median 100 (50-200) Median 20 (1-115) Median 50 (15-116) Surgery
Median 17 (4 -100) No Surgery
Cancer Stage
Stage I
Stage II
Stage III
1 (25%)
2 (50%)
1 (25%)
5 (50%)
4 (40%)
1 (10%)
Location 100% Right side
50% Left side
100% Rectum
80% Colon
20% Rectum
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underwent segmental colectomy, 5 underwent a colect-
omy with ileorectal anastomosis, and 5 were treated
with total proctocolectomy (4 with ileal anal pouch and
one with an end ileostomy). There have been no deaths
from colon or rectal cancer and no recurrence at a
mean follow-up of 96 months.
Conclusion
MAP is associated with an increased risk of colorectal
cancer, but appropriate surveillance and surgical inter-
vention prevents cancer-related deaths.
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